Clinical trials: Esophageal Varices
High Risk Esophageal Varices
Spleen Stiffness as a Measure to Assess the REsponse to β Blocker Therapy (SPARE-B)
HVPG is the gold standard for measurement of the presence and severity of portal hypertension. Clinically Significant Portal Hypertension (CSPH) is defined as HVPG ≥ 10 mmHg.
- Trial name
- NCT06050837
- Testing
- No intervention
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Esophageal and Gastric Varices
The Diagnostic Value of Subharmonic Imaging Technology Combined With Liver Stiffness and Platelet Count for High-risk Esophageal and Gastric Varices in Patients With Liver Cirrhosis
To evaluate the diagnostic value of the combined model of subharmonic-assisted pressure estimation (SHAPE), liver stiffness (LSM), and platelet count (PLT) for high-risk esophageal and gastric varices (HRV)
- Trial name
- NCT07151885
- Testing
- SHAPE
- Where
- China
- Volunteers
- 380 people
- Sponsor
- The First Hospital of Jilin University
Cirrhosis, Portal Vein Thrombosis
Safety of Anticoagulant Therapy After Endoscopic Treatment
The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.
- Conditions
- Cirrhosis, Portal Vein Thrombosis, Esophageal and Gastric Varices, Anticoagulant-induced Bleeding
- Trial name
- NCT04976543
- Testing
- nadroparin calcium-warfarin sequential anticoagulation
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Qilu Hospital of Shandong University
Esophageal Varices
A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.
To evaluate the efficacy and safety of early postoperative oral intake (with a fasting period of 6 hours) versus delayed postoperative oral intake (with fasting periods of 24 hours or 48 hours) in patients with cirrhosis…
- Trial name
- NCT07774143
- Testing
- fasting periods of 24 hours, fasting periods of 48 hours, fasting periods of 6 hours
- Where
- 12 sites in China
- Volunteers
- 339 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Cirrhosis
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD.
- Trial name
- NCT01212250
- Testing
- carvedilol
- Where
- India
- Volunteers
- 132 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hematemesis, Portal Hypertension
Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope
Band ligation and injection sclerotherapy are two modalities of treatment that are applied using the endoscope. The purpose of this study is to determine which of two methods is better for controlling bleeding from the upper gut.
- Trial name
- NCT01131962
- Testing
- Endoscopic control of hematemesis
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- University of Alexandria
Esophageal Varices, Portal Hypertension
Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding
The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.
- Conditions
- Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
- Trial name
- NCT00331188
- Testing
- Sanvar® (vapreotide)
- Where
- 19 sites in United States
- Volunteers
- 70 people
- Sponsor
- Debiovision
Portopulmonary Hypertension
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
This is an Open Label, Multicenter, pilot clinical trial to assess the efficacy and safety of an oral selective Endothelin Receptor Antagonist (ambrisentan) in patients with portopulmonary hypertension.
- Trial name
- Portopulm (NCT01224210)
- Testing
- Ambrisentan
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tufts Medical Center
Esophageal Varices in Cirrhosis of the Liver
Magnetic-assisted Capsule Endoscope With 3D Images in EV Detection in Cirrhotic Patient
Newly development of capsule endoscopy provides a comfortable and minimal invasive modality which is an alternative to conventional esophagogastroduodenoscopy(EGD).
- Trial name
- NCT04588974
- Testing
- magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Esophageal and Gastric Varices
Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy
In the Western world, liver cirrhosis is a significant issue. Acute variceal bleeding (AVB) is a considerable complication of cirrhosis associated with high mortality.
- Trial name
- NCT05331768
- Testing
- banding ligation plus terlipressin infusion
- Where
- Mexico
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Cirrhosis, Esophageal and Gastric Varices
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.
- Conditions
- Cirrhosis, Esophageal and Gastric Varices, Gastrointestinal Hemorrhage
- Trial name
- RFXM (NCT02991612)
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Zhongshan Hospital
Portal Hypertension, Cirrhosis
MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
Background: Standardization and new therapeutic treatments of variceal bleeding has significantly reduced the mortality the last 25 years, but there is still a high 6-week mortality around 15-20% and 1-year mortality of about…
- Conditions
- Portal Hypertension, Cirrhosis, Esophageal Varices, Gastric Varices Bleeding
- Trial name
- NCT03438916
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Esophageal and Gastric Varices, Liver Cirrhosis
Prevention of Esophageal Varices by Beta-Adrenergic Blockers
The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease.
- Conditions
- Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
- Trial name
- NCT00006398
- Testing
- Timolol Maleate
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 213 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Portal Hypertension, Cirrhosis
Esophageal Capsule Endoscopy in Children
The portal hypertension (PHT) is the main complication in patients presenting with cirrhosis. It can be the direct cause of bleeding by rupture of the esophageal or gastric varices and can also contribute to the development of…
- Trial name
- PREVOCAP (NCT01551966)
- Testing
- Wireless esophageal capsule endoscopy ( PillCam Eso2)
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Esophageal Varices
Noninvasive Methods For Prediction of Esophageal Varices in Children
The aim of this study is to use non-invasive methods to identify patients at risk of developing gastrointestinal varices and correlation of these non-invasive methods with the degree of esophageal varices and the presence or…
- Trial name
- NCT05781828
- Testing
- Detailed abdominal ultrasound
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Acute on Chronic Liver Failure
Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices
Acute on chronic liver failure patients with HVPG (Hepatic Venous Pressure Gradient) ≥ 12 mmHg + No/small esophageal varices who present to the Department of Hepatology at Institute of Liver and Billiary Sciences, who meet the…
- Trial name
- NCT02583698
- Testing
- Carvedilol
- Where
- India
- Volunteers
- 136 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Portal Hypertension
Danish Carvedilol Study in Portal Hypertension
Patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding.
- Trial name
- DACAPO (NCT00493480)
- Testing
- carvedilol, propranolol
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Esophageal Varices
Enhancing Detection of Small Esophageal Varices by PillCam ESO
Increasing intra-abdominal pressure (IAP) with an abdominal binder will increase pressure within smaller esophageal varices which will therefore enhance the ability of capsule endoscopy to detect these varices better.
- Trial name
- NCT00911131
- Testing
- Capsule endoscopy (PillCam ESO), EGD, Capsule endoscopy (PillCam ESO) with abdominal binder
- Sponsor
- Medical College of Wisconsin
Esophageal and Gastric Varices, Liver Cirrhosis
Pantoprazole After Prophylactic Endoscopic Variceal Treatment
Traditionally, it is considered that gastric acid delays ulcer healing, and acid suppression can reduce the risk of post-banding ulcer bleeding and promote mucosal healing at the ulcer site.
- Trial name
- NCT07248722
- Testing
- Pantoprazole
- Where
- China
- Volunteers
- 208 people
- Sponsor
- General Hospital of Shenyang Military Region
Esophageal and Gastric Varices, Liver Cirrhosis
Decompression Intervention of Variceal Rebleeding Trial (DIVERT)
The Decompression Intervention of Variceal Rebleeding Trial (DIVERT) is a multi-center prospective randomized clinical trial comparing the radiologic procedure of transjugular intrahepatic portal-systemic shunt (TIPS) with the…
- Trial name
- NCT00006161
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Distal Splenorenal Shunt
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)